Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
An Open Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein Barr Virus Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL 1)
NCT Number:
NCT05011058
Phase:
II
Protocol Type:
Treatment
Age Group:
Both
Disease Sites:
Other Hematopoietic
Study Objectives:
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas.
Study Documents
(MUSC NetID required for document access)